Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer
Figure 4
Overall survival according to the number of molecular abnormalities within individual tumor samples.
Data from the cohort of patients with a known molecular status of all four markers.